Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Effectiveness of the Pulsar-18 self-expanding stent with optional drug-coated balloon angioplasty in the treatment of femoropopliteal lesions - the BIOFLEX PEACE All-Comers Registry.

Lichtenberg M, Breuckmann F, Kramer V, Betge S, Sixt S, Hailer B, Nikol S, Arjumand J, Wittenberg G, Teßarek J, Nolte-Ernsting C.

Vasa. 2019 Mar 29:1-8. doi: 10.1024/0301-1526/a000785. [Epub ahead of print]

PMID:
30924409
2.

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy.

Pastori D, Eikelboom JW, Anand SS, Patel MR, Tanguay JF, Ricco JB, Debus ES, Mazzolai L, Bauersachs R, Verhamme P, Bosch J, Nikol S, Nehler M, Aboyans V, Violi F.

Thromb Haemost. 2019 Apr;119(4):576-585. doi: 10.1055/s-0039-1678527. Epub 2019 Jan 31.

PMID:
30703812
3.

PLX-PAD Cell Treatment of Critical Limb Ischaemia: Rationale and Design of the PACE Trial.

Norgren L, Weiss N, Nikol S, Hinchliffe RJ, Lantis JC, Patel MR, Reinecke H, Ofir R, Rosen Y, Peres D, Aberman Z.

Eur J Vasc Endovasc Surg. 2019 Apr;57(4):538-545. doi: 10.1016/j.ejvs.2018.11.008. Epub 2019 Jan 25.

PMID:
30686676
4.

ESVM guidelines - the diagnosis and management of Raynaud's phenomenon.

Belch J, Carlizza A, Carpentier PH, Constans J, Khan F, Wautrecht JC, Visona A, Heiss C, Brodeman M, Pécsvárady Z, Roztocil K, Colgan MP, Vasic D, Gottsäter A, Amann-Vesti B, Chraim A, Poredoš P, Olinic DM, Madaric J, Nikol S, Herrick AL, Sprynger M, Klein-Weigel P, Hafner F, Staub D, Zeman Z.

Vasa. 2017 Oct;46(6):413-423. doi: 10.1024/0301-1526/a000661. Epub 2017 Sep 12. Review.

5.

Self-Expanding Versus Balloon-Expandable Stents for Iliac Artery Occlusive Disease: The Randomized ICE Trial.

Krankenberg H, Zeller T, Ingwersen M, Schmalstieg J, Gissler HM, Nikol S, Baumgartner I, Diehm N, Nickling E, Müller-Hülsbeck S, Schmiedel R, Torsello G, Hochholzer W, Stelzner C, Brechtel K, Ito W, Kickuth R, Blessing E, Thieme M, Nakonieczny J, Nolte T, Gareis R, Boden H, Sixt S.

JACC Cardiovasc Interv. 2017 Aug 28;10(16):1694-1704. doi: 10.1016/j.jcin.2017.05.015.

6.

[Treatment and Secondary Prevention of Venous Thromboembolism - Change in Oral Anticoagulation].

Helms TM, Gulba D, Ahrens I, Schäfer A, Hankowitz J, Kuhlencordt P, Lipp HP, Nikol S, Riess H, Stargardt T, Bramlage P.

Dtsch Med Wochenschr. 2017 Jul;142(13):986-993. doi: 10.1055/s-0042-124132. Epub 2017 Apr 19. Review. German.

PMID:
28423431
7.

Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries.

Fowkes FG, Forster RB, Levin CE, Naidoo NG, Roy A, Shu C, Spertus J, Fang K, Bechara-Zamudio L, Catalano M, Visonà A, Nikol S, Fletcher JP, Jaff MR, Hiatt WR, Norgren L.

Int Angiol. 2017 Jun;36(3):203-215. doi: 10.23736/S0392-9590.16.03716-0. Epub 2016 Jul 7. Review.

8.

UEMS training requirements for angiology and vascular medicine: european standards of postgraduate medical specialist training (ETR Document).

Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Dimakakos EP, Marakomichelakis G, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Amann-Vesti B, Gallino A, Fitzgerald P, Colgan MP.

Int Angiol. 2016 Apr;35(2):217-31. Epub 2016 Feb 16. No abstract available.

9.

First report on an inotropic peptide activating tetrodotoxin-sensitive, "neuronal" sodium currents in the heart.

Kirchhof P, Tal T, Fabritz L, Klimas J, Nesher N, Schulte JS, Ehling P, Kanyshkova T, Budde T, Nikol S, Fortmueller L, Stallmeyer B, Müller FU, Schulze-Bahr E, Schmitz W, Zlotkin E, Kirchhefer U.

Circ Heart Fail. 2015 Jan;8(1):79-88. doi: 10.1161/CIRCHEARTFAILURE.113.001066. Epub 2014 Nov 25.

PMID:
25424392
10.

Angiogenic gene therapy does not cause retinal pathology.

Prokosch V, Stupp T, Spaniol K, Pham E, Nikol S.

J Gene Med. 2014 Sep-Oct;16(9-10):309-16. doi: 10.1002/jgm.2806.

PMID:
25322754
11.

Activity of daily living is associated with circulating CD34+/KDR+ cells and granulocyte colony-stimulating factor levels in patients after myocardial infarction.

Krüger K, Klocke R, Kloster J, Nikol S, Waltenberger J, Mooren FC.

J Appl Physiol (1985). 2014 Mar 1;116(5):532-7. doi: 10.1152/japplphysiol.01254.2013. Epub 2014 Jan 9.

12.

Generation of functional endothelial-like cells from adult mouse germline-derived pluripotent stem cells.

Kim J, Eligehausen S, Stehling M, Nikol S, Ko K, Waltenberger J, Klocke R.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):700-5. doi: 10.1016/j.bbrc.2013.12.035. Epub 2013 Dec 12.

PMID:
24333870
13.

Requirements for angiology/vascular medicine.

Catalano M, Poredos P, Brodmann M, Wautrecht JC, Carpentier P, Roztocil K, Nikol S, Diamantopoulos E, Pecsvarady Z, Carlizza A, Sieron A, Stanek A, Olinic D, Stvrtinova V, Kozak M, Agewall S, Gallino A, Jaeger KA, Fitzgerald P, Colgan MP.

Int Angiol. 2013 Dec;32(6):608-12. No abstract available.

PMID:
24212296
14.
15.

Exercise delays neutrophil apoptosis by a G-CSF-dependent mechanism.

Mooren FC, Völker K, Klocke R, Nikol S, Waltenberger J, Krüger K.

J Appl Physiol (1985). 2012 Oct;113(7):1082-90. doi: 10.1152/japplphysiol.00797.2012. Epub 2012 Aug 2.

16.

[Stem cell therapy in vascular medicine].

Nikol S.

Zentralbl Chir. 2011 Oct;136(5):399-403. Review. German. No abstract available.

PMID:
22121537
17.

Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure.

Milberg P, Pott C, Frommeyer G, Fink M, Ruhe M, Matsuda T, Baba A, Klocke R, Quang TH, Nikol S, Stypmann J, Osada N, Müller FU, Breithardt G, Noble D, Eckardt L.

Heart Rhythm. 2012 Apr;9(4):570-8. doi: 10.1016/j.hrthm.2011.11.004. Epub 2011 Nov 7.

PMID:
22075452
18.

G-CSF therapy reduces myocardial repolarization reserve in the presence of increased arteriogenesis, angiogenesis and connexin 43 expression in an experimental model of pacing-induced heart failure.

Milberg P, Klocke R, Frommeyer G, Quang TH, Dieks K, Stypmann J, Osada N, Kuhlmann M, Fehr M, Milting H, Nikol S, Waltenberger J, Breithardt G, Eckardt L.

Basic Res Cardiol. 2011 Nov;106(6):995-1008. doi: 10.1007/s00395-011-0230-8. Epub 2011 Nov 10.

PMID:
22072114
19.

Gene therapy in vascular disease.

Sedighiani F, Nikol S.

Surgeon. 2011 Dec;9(6):326-35. doi: 10.1016/j.surge.2011.05.003. Epub 2011 Jul 5. Review.

PMID:
22041646
20.

Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease.

Niebuhr A, Henry T, Goldman J, Baumgartner I, van Belle E, Gerss J, Hirsch AT, Nikol S.

Gene Ther. 2012 Mar;19(3):264-70. doi: 10.1038/gt.2011.85. Epub 2011 Jun 30.

PMID:
21716303
21.

Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia.

Van Belle E, Nikol S, Norgren L, Baumgartner I, Driver V, Hiatt WR, Belch J.

Eur J Vasc Endovasc Surg. 2011 Sep;42(3):365-73. doi: 10.1016/j.ejvs.2011.04.030. Epub 2011 Jun 21.

22.

Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia.

Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L, Van Belle E; TAMARIS Committees and Investigators.

Lancet. 2011 Jun 4;377(9781):1929-37. doi: 10.1016/S0140-6736(11)60394-2. Epub 2011 May 28.

PMID:
21621834
23.

[Therapeutic angiogenesis using gene transfer and stem cell therapy in peripheral artery disease].

Nikol S.

Dtsch Med Wochenschr. 2011 Apr;136(14):672-4. doi: 10.1055/s-0031-1274561. Epub 2011 Mar 29. Review. German.

PMID:
21448824
24.

A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial.

Kastrup J, Jørgensen E, Fuchs S, Nikol S, Bøtker HE, Gyöngyösi M, Glogar D, Kornowski R.

EuroIntervention. 2011 Feb;6(7):813-8. doi: 10.4244/EIJV6I7A140.

25.

Effects of G-CSF treatment on neutrophil mobilization and neurological outcome after transient focal ischemia.

Strecker JK, Sevimli S, Schilling M, Klocke R, Nikol S, Schneider A, Schäbitz WR.

Exp Neurol. 2010 Mar;222(1):108-13. doi: 10.1016/j.expneurol.2009.12.012. Epub 2009 Dec 21.

PMID:
20026112
26.

The role of granulocyte-colony stimulating factor (G-CSF) in the healthy brain: a characterization of G-CSF-deficient mice.

Diederich K, Sevimli S, Dörr H, Kösters E, Hoppen M, Lewejohann L, Klocke R, Minnerup J, Knecht S, Nikol S, Sachser N, Schneider A, Gorji A, Sommer C, Schäbitz WR.

J Neurosci. 2009 Sep 16;29(37):11572-81. doi: 10.1523/JNEUROSCI.0453-09.2009.

27.

Endogenous brain protection by granulocyte-colony stimulating factor after ischemic stroke.

Sevimli S, Diederich K, Strecker JK, Schilling M, Klocke R, Nikol S, Kirsch F, Schneider A, Schäbitz WR.

Exp Neurol. 2009 Jun;217(2):328-35. doi: 10.1016/j.expneurol.2009.03.018. Epub 2009 Mar 28.

PMID:
19332060
28.

Gene therapy of cardiovascular disease.

Nikol S.

Curr Opin Mol Ther. 2008 Oct;10(5):479-92. Review.

PMID:
18830924
29.

Meta-analysis shows similar risk of thrombosis after drug-eluting stent, bare-metal stent, or angioplasty.

Fuchs AT, Kuehnl A, Pelisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S.

Endothelium. 2008 Jan-Feb;15(1):93-100. doi: 10.1080/10623320802092534.

PMID:
18568949
30.

Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty?

Fuchs AT, Kuehnl A, Pelisek J, Rolland PH, Mekkaoui C, Netz H, Nikol S.

Endothelium. 2008 Jan-Feb;15(1):85-92. doi: 10.1080/10623320802092484.

PMID:
18568948
31.

Therapeutic Angiogenesis With Intramuscular NV1FGF Improves Amputation-free Survival in Patients With Critical Limb Ischemia.

Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Graham Wyatt M, Dinesh Wijesinghe L, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F.

Mol Ther. 2008 May;16(5):972-978. doi: 10.1038/mt.2008.33. Epub 2016 Dec 8.

PMID:
28178491
32.

Granulocyte colony-stimulating factor (G-CSF) for cardio- and cerebrovascular regenerative applications.

Klocke R, Kuhlmann MT, Scobioala S, Schäbitz WR, Nikol S.

Curr Med Chem. 2008;15(10):968-77. Review.

PMID:
18393854
33.

Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia.

Nikol S, Baumgartner I, Van Belle E, Diehm C, Visoná A, Capogrossi MC, Ferreira-Maldent N, Gallino A, Wyatt MG, Wijesinghe LD, Fusari M, Stephan D, Emmerich J, Pompilio G, Vermassen F, Pham E, Grek V, Coleman M, Meyer F; TALISMAN 201 investigators.

Mol Ther. 2008 May;16(5):972-8. doi: 10.1038/mt.2008.33. Epub 2008 Apr 1.

34.

Therapeutic angiogenesis for peripheral artery disease: cytokine therapy.

Kuhlmann MT, Klocke R, Nikol S.

Vasa. 2007 Nov;36(4):253-60. Review.

PMID:
18357917
35.

Therapeutic angiogenesis for peripheral artery disease: stem cell therapy.

Lachmann N, Nikol S.

Vasa. 2007 Nov;36(4):241-51. Review.

PMID:
18357916
36.
37.

Current biotechnological approaches to the prevention of restenosis.

Nikol S, Maier A, Krausz E, Höfling B, Huehns TY.

BioDrugs. 1998 May;9(5):375-88.

PMID:
18020572
38.

Therapeutic angiogenesis for peripheral artery disease: gene therapy.

Nikol S.

Vasa. 2007 Aug;36(3):165-73. Review.

PMID:
18019272
39.

Up-regulation of nestin in the infarcted myocardium potentially indicates differentiation of resident cardiac stem cells into various lineages including cardiomyocytes.

Scobioala S, Klocke R, Kuhlmann M, Tian W, Hasib L, Milting H, Koenig S, Stelljes M, El-Banayosy A, Tenderich G, Michel G, Breithardt G, Nikol S.

FASEB J. 2008 Apr;22(4):1021-31. Epub 2007 Nov 5.

PMID:
17984177
40.

Small poly-L-lysines improve cationic lipid-mediated gene transfer in vascular cells in vitro and in vivo.

Golda A, Pelisek J, Klocke R, Engelmann MG, Rolland PH, Mekkaoui C, Nikol S.

J Vasc Res. 2007;44(4):273-82. Epub 2007 Mar 30.

PMID:
17406119
41.

Viral or non-viral angiogenesis gene transfer-New answers to old questions.

Nikol S.

Cardiovasc Res. 2007 Feb 1;73(3):443-5. Epub 2006 Dec 8. No abstract available.

PMID:
17196566
42.

Surgical animal models of heart failure related to coronary heart disease.

Klocke R, Tian W, Kuhlmann MT, Nikol S.

Cardiovasc Res. 2007 Apr 1;74(1):29-38. Epub 2006 Nov 23. Review.

PMID:
17188668
43.

Granulocyte colony-stimulating factor and acute myocardial infarction.

Schäbitz WR, Nikol S, Schneider A.

JAMA. 2006 Oct 25;296(16):1967-8; author reply 1968-9. No abstract available.

PMID:
17062856
44.

Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model.

Tian W, Kuhlmann MT, Pelisek J, Scobioala S, Quang TH, Hasib L, Klocke R, Jahn UR, Nikol S.

J Endovasc Ther. 2006 Oct;13(5):616-29.

PMID:
17042659
45.

[Mobilization of stem cells in cardiovascular disease. Improvement of vascularization, cardiac function and arrhythmias].

Nikol S, Kuhlmann M.

Med Klin (Munich). 2006 Mar 22;101 Suppl 1:190-2. German.

PMID:
16802552
46.

C-type natriuretic peptide for reduction of restenosis: gene transfer is superior over single peptide administration.

Pelisek J, Fuchs AT, Kuehnl A, Tian W, Kuhlmann MT, Rolland PH, Mekkaoui C, Gaedtke L, Nikol S.

J Gene Med. 2006 Jul;8(7):835-44.

PMID:
16602133
47.

Chronic perivascular inoculation with Chlamydophila pneumoniae results in plaque formation in vivo.

Engelmann MG, Redl CV, Pelisek J, Barz C, Heesemann J, Nikol S.

Lab Invest. 2006 May;86(5):467-76.

48.

Adventitial VEGF165 gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries.

Deiner C, Schwimmbeck PL, Koehler IS, Loddenkemper C, Noutsias M, Nikol S, Schultheiss HP, Ylä-Herttuala S, Pels K.

Atherosclerosis. 2006 Nov;189(1):123-32. Epub 2006 Jan 24.

PMID:
16434047
49.

G-CSF/SCF reduces inducible arrhythmias in the infarcted heart potentially via increased connexin43 expression and arteriogenesis.

Kuhlmann MT, Kirchhof P, Klocke R, Hasib L, Stypmann J, Fabritz L, Stelljes M, Tian W, Zwiener M, Mueller M, Kienast J, Breithardt G, Nikol S.

J Exp Med. 2006 Jan 23;203(1):87-97. Epub 2006 Jan 9.

50.

Optimized lipopolyplex formulations for gene transfer to human colon carcinoma cells under in vitro conditions.

Pelisek J, Gaedtke L, DeRouchey J, Walker GF, Nikol S, Wagner E.

J Gene Med. 2006 Feb;8(2):186-97.

PMID:
16245365

Supplemental Content

Support Center